Head-to-head comparisons of medication uses, side effects, warnings, and more.
Key takeaways
Baricitinib (Olumiant) and upadacitinib (Rinvoq) are both Janus kinase (JAK) inhibitors used to treat rheumatoid arthritis (RA). However, they have different FDA-approved uses and dosing. Baricitinib is also approved for severe hair loss (alopecia areata) and COVID-19 in hospitalized adults needing breathing support, while upadacitinib is used for conditions like ulcerative colitis, eczema, and Crohn's disease, among others. Baricitinib is taken as a 2 mg or 4 mg tablet once daily, depending on the condition, while upadacitinib is typically taken as a 15 mg tablet once daily, with some conditions requiring a higher dose. Upadacitinib is available in both tablet and liquid forms, unlike baricitinib, which is only available as a tablet. Both medications can increase the risk of infections and have potential drug interactions. You should avoid grapefruit juice with upadacitinib due to a potential interaction. Both medications require careful monitoring.
Rinvoq (upadacitinib) is a Janus kinase (JAK) inhibitor. It's used to treat certain inflammatory conditions, such as rheumatoid arthritis (RA), ulcerative colitis (UC), and eczema (atopic dermatitis). But it's not a first-choice option and typically only prescribed when other treatments haven't worked well. Rinvoq (upadacitinib) is taken by mouth, usually once daily. It's available as an extended-release tablet (Rinvoq) and an oral solution (Rinvoq LQ), but the two formulations aren't interchangeable. Side effects include a higher risk of infections, acne, and nausea.